Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 7/20 | 0.52 |
| ▸ | LAP3 | P28838 | 6/20 | 0.52 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.52 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1582588 | 1.00 | ANPEP (0.52) | ANPEPLAP3ERAP1ERAP2ALDH1A1 | |
| SCHEMBL30268938 | 1.00 | ANPEP (0.52) | ANPEPLAP3ERAP1ERAP2ALDH1A1 | |
| SCHEMBL14181994 | 0.73 | ANPEP (0.52) | ANPEPLAP3ERAP1ERAP2TDP1 | |
| SCHEMBL3482857 | 0.73 | ANPEP (0.52) | ANPEPLAP3ERAP1ERAP2TDP1 | |
| SCHEMBL6916280 | 0.72 | LAP3 (0.35) | ANPEPLAP3ERAP1ALDH1A1TDP1 | |
| SCHEMBL3375511 | 0.72 | — | — | |
| SCHEMBL19883375 | 0.72 | — | — | |
| SCHEMBL16393940 | 0.72 | — | — | |
| SCHEMBL6051930 | 0.70 | — | — | |
| Leucine Phosphonic Acid SCHEMBL3079895 | 0.69 | LAP3 (1.00) | ANPEPLAP3ERAP1ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6762174-B1 | BETA-ALETHINE WITH MELPHALAN OR CYCLOPHOSPHAMIDE; PREVENTS CLINICAL APPEARANCE OF A NEOPLASTIC OR PRE-NEOPLASTIC CONDITION; IMMUNOMODULATION; ENHANCING CELL GROWTH, VITALITY, DIFFERENTIATION; ANTISENESCENCE | DOVETAIL TECHNOLOGIES, INC. | 2004-07-13 | — | — | US | disclosed |
| US-6498150-B2 | USEFUL IN ENHANCING VACCINATION, INCREASING SYNTHESIS AND FUNCTION OF BLOOD CELL COMPONENTS, AND ENHANCING ANTITUMOR EFFECTS | DOVETAIL TECHNOLOGIES, INC. | 2002-12-24 | — | — | US | disclosed |
| US-20020035118-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | DOVETAIL TECHNOLOGIES INC. | 2002-03-21 | — | — | US | disclosed |
| US-6007819-A | Methods of inducing immunity using low molecular weight immune stimulants | DOVETAIL TECHNOLOGIES, INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999042097-A1 | SMALL MOLECULES THAT ELICIT A POLARIZED TH1 RESPONSE AND FOR MODULATION OF CELLULAR IMMUNITY | DOVETAIL TECHNOLOGIES INC. (US) | 1999-08-26 | — | — | WO | disclosed |
| WO-1997014306-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | DOVETAIL TECHNOLOGIES, INC. (US) | 1997-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035118-A1 | LOW MOLECULAR WEIGHT CELL, BONE MARROW AND IMMUNE STIMULANTS | ACP1, CD14, HPGDS | ANPEP 149/4885LAP3 1175/4885ERAP1 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.